Adverse Events Associated with Oral First-in-Man Administration of New Chemical Entities Compared with Placebo – An Analysis of 14 Single- and Multi-Dosing, Double-Blind, Placebo-Controlled Studies

Authors

  • Rahul S Dimber
  • Peter Dewland

DOI:

https://doi.org/10.37591/rrjot.v2i3.1280

Abstract

This investigation is a retrospective analysis of the adverse events (AEs) associated with oral administration of new chemical entities (NCEs)for the first time in humans. We gathered data from 14 single- and multiple-dosings of FIM NCE studies conducted in our centre over a period of 5 years. In total, 452 subjects were dosed. A total of 2280 doses were administered. Active medication was given on 1763 dosing occasions and placebo was given on 517 dosing. 74.9% of AEs of active and 95.6% of AEs on placebo were mild. The most common AE (incidence of more than 2%) on active medication and placebo were headache, nausea, dizziness, diarrhoea, dry mouth, fatigue, tachycardia, insomnia, abnormal dreams and abdominal pain. Except for nausea and diarrhoea, which was more in the active group, there was no statistically significant difference for other AEs between active and placebo.

Keywords: AE, placebo effect, nocebo effect

Downloads

Published

2019-04-05

Issue

Vol. 2 No. 3 (2012)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.